Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) has announced the inclusion of a novel molecule with potentially heart-safe microdose enabling properties in its family of psilocin analogs.
The Denver-based company has named this group of patent-pending molecules MYCO-005.
Microdosing refers to consuming a very low dose of a psychedelic substance to retain some of the benefits without undergoing a psychoactive experience. Although microdosing has been gaining popularity in mainstream media as a possible treatment for indications such as ADHD, depression, and anxiety, more research is needed to confirm the safety and efficacy of this method.
READ: Mydecine Innovations says its exclusive dealer identified as licensed psilocybin and MDMA supplier in Canada
“When you consider any drug intended to be taken over a long period of time, there is often a strong medical risk involved,” said Mydecine chief scientific officer Rob Roscow in a statement. “When it comes to psilocybin, in particular, there are cardiovascular health concerns due to the binding affinity to the 5-HT2B receptor.”
Previous studies have drawn connections between binding to the 5-HT2B receptor and heart valve tissue fibrosis, the company noted.
Classic psilocybin, or psilocin –its active metabolite, has a strong binding affinity to both the 5-HT2A and 5-HT2B serotonin receptors. Therefore, consuming low doses of psilocybin over a long period of time could cause certain cardiac risks.
“Through our ongoing research, we have found that one of our psilocin analogs is showing strong binding at the classic psychedelic 5-HT2A receptor, but is not binding to the 5-HT2B receptor,” said Roscow.
He added that this is a strong indication that the company’s improved psilocin analog could potentially produce the same benefits of natural psilocybin with an increased safety profile for microdosing.
In December of 2021, Mydecine announced a patent application covering multiple families of psilocin analogs, MYCO-005. This family of second-generation molecules directly addresses delivery and stability concerns with the first-generation compounds.
The company’s patent-pending dermal route to administration provides more control over the drug while potentially eliminating undesirable properties like nausea by bypassing the digestive system. Mydecine’s research will explore this new feature set alongside their patent-pending skin permeation technology to produce a low-dosed, time-released patch drug that is non-hallucinatory.
“We are very excited about our MYCO-005 family of molecules,” said CEO Josh Bartch. “Not only have we made improvements to this second generation of compounds to specifically address concerns for medical use, like onset time and shelf stability, but now we believe we have also identified a microdosing compound that is safer than what’s currently available on the market.”
Contact Ritika at ritika@proactiveinvestors.com